Humacyte Historical Balance Sheet
| HUMAW Stock | USD 1.47 0.03 2.00% |
Trend analysis of Humacyte balance sheet accounts such as Other Current Liabilities of 7.2 M or Total Current Liabilities of 15.7 M provides information on Humacyte's total assets, liabilities, and equity, which is the actual value of Humacyte to its prevalent stockholders. By breaking down trends over time using Humacyte balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.
Financial Statement Analysis is much more than just reviewing and examining Humacyte latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Humacyte is a good buy for the upcoming year.
Humacyte Inventory |
|
Humacyte |
About Humacyte Balance Sheet Analysis
Balance Sheet is a snapshot of the financial position of Humacyte at a specified time, usually calculated after every quarter, six months, or one year. Humacyte Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Humacyte and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Humacyte currently owns. An asset can also be divided into two categories, current and non-current.
Humacyte Balance Sheet Chart
Add Fundamental
Total Assets
Total assets refers to the total amount of Humacyte assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Humacyte books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.Total Current Liabilities
Total Current Liabilities is an item on Humacyte balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Humacyte are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.Net Debt
The total debt of a company minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds.Long Term Debt
Long-term debt is a debt that Humacyte has held for over one year. Long-term debt appears on Humacyte balance sheet and also includes long-term leases. The most common forms of long term debt are bonds payable, long-term notes payable, mortgage payable, pension liabilities, and lease liabilities. In the corporate world, long-term debt is generally used to fund big-ticket items, such as machinery, buildings, and land. The total of long-term debt reported on Humacyte balance sheet is the sum of the balances of all categories of long-term debt. Debt that is not due within the current year and is often considered to be financing activities that are to be repaid over several years.Most accounts from Humacyte's balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Humacyte current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Humacyte. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For more information on how to buy Humacyte Stock please use our How to Invest in Humacyte guide.At this time, Humacyte's Other Current Assets are fairly stable compared to the past year. Total Liabilities is likely to climb to about 137.6 M in 2024, whereas Total Current Liabilities is likely to drop slightly above 15.7 M in 2024.
| 2021 | 2022 | 2023 | 2024 (projected) | Short and Long Term Debt Total | 48.5M | 47.8M | 58.1M | 45.9M | Total Assets | 286.5M | 204.3M | 128.2M | 196.8M |
Humacyte balance sheet Correlations
Click cells to compare fundamentals
Humacyte Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Humacyte Stock Analysis
When running Humacyte's price analysis, check to measure Humacyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Humacyte is operating at the current time. Most of Humacyte's value examination focuses on studying past and present price action to predict the probability of Humacyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Humacyte's price. Additionally, you may evaluate how the addition of Humacyte to your portfolios can decrease your overall portfolio volatility.